BCRX241220C9000
- 0.05
- 0.000.00%
BioCryst Pharmaceuticals Newsroom
Bullish BioCryst Pharmaceuticals Insiders Loaded Up On US$1.05m Of Stock
BioCryst Pharmaceuticals' Hereditary Angioedema Drug Gets Recommendation From Ireland Regulator
BioCryst Launches ORLADEYO (Berotralstat) in Ireland
BofA Securities Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating
BioCryst (BCRX) Receives a Buy From Bank of America Securities
When Will BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Become Profitable?
BioCryst to Present at Upcoming Investor Conferences
BioCryst Pharmaceuticals | 10-Q: Q3 2024 Earnings Report
BioCryst Pharmaceuticals Price Target Maintained With a $14.00/Share by Needham
BioCryst Pharmaceuticals Is Maintained at Equal-Weight by Barclays
BioCryst Pharma Analyst Ratings
RBC Capital Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $10
Evercore Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $10
A Quick Look at Today's Ratings for BioCryst Pharmaceuticals(BCRX.US), With a Forecast Between $8 to $30
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Express News | BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Express News | BioCryst Pharmaceuticals, Inc. : Barclays Raises Target Price to $8 From $7
Earnings Call: BioCryst Pharmaceuticals Reports Strong Q3 Growth
12 Health Care Stocks Moving In Monday's Intraday Session
BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2024 Earnings Call Transcript Summary